三种β-内酰胺类抗菌药物分别联合阿奇霉素治疗儿童肺炎支原体肺炎的成本-效果分析  

Cost-Effectiveness Analysis on Three Kinds of β-lactams in Respectively Combination with Azithromycin in Treatment of Children with Mycoplasma Pneumoniae Pneumonia

作　　者：张伟[1] 陈宗玮[1] ZHANG Wei;CHEN Zongwei(Dept.of Pharmacy, Jiujiang Maternal and Child Health Hospital, Jiangxi Jiujiang 332000, China)

机构地区：[1]九江市妇幼保健院药剂科,江西九江332000

出　　处：《中国医院用药评价与分析》2019年第4期445-447,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨三种β-内酰胺类抗菌药物分别联合阿奇霉素治疗儿童肺炎支原体肺炎的经济性。方法:回顾性选取2017年1月至2018年6月九江市妇幼保健院收治的肺炎支原体肺炎患儿113例,按照治疗方案的不同分为A组(头孢他啶联合阿奇霉素)32例、B组(头孢噻肟钠联合阿奇霉素)44例和C组(阿莫西林克拉维酸钾联合阿奇霉素)37例。观察三组患儿的临床疗效、不良反应发生情况,并进行成本-效果分析。结果:A、B和C组患儿的有效率分别为93.8%(30/32)、95.5%(42/44)和91.9%(34/37),差异均无统计学意义(P>0.05)。三组患儿均未发生明显不良反应。A、B和C组患儿的药品费用分别为(904.75±342.33)、(756.13±397.20)和(669.06±147.31)元。C组方案的成本-效果比最低,最具药物经济学优势,敏感度分析也证实此结果。结论:三种方案治疗儿童肺炎支原体肺炎的效果相当,其中阿莫西林克拉维酸钾联合阿奇霉素方案所需成本最低,也是最具药物经济学优势的方案。OBJECTIVE: To probe into the economical efficiency of three kinds of β-lactams in respectively combination with azithromycin in treatment of children with mycoplasma pneumoniae pneumonia. METHODS: 113 children with mycoplasma pneumoniae pneumonia admitted into Jiujiang Maternal and Child Health Hospital from Jan. 2017 to Jun. 2018 were retrospectively selected and divided into group A(ceftazidime combined with azithromycin, 32 cases), group B(cefotaxime sodium combined with azithromycin, 44 cases) and group C(amoxicillin-clavulanate potassium combined with azithromycin, 37 cases) according to different therapeutic regimens. The clinical efficacy and incidences of adverse drug reactions of three groups were observed with cost-effectiveness analysis. RESULTS: The total effective rates of group A, group B and group C were respectively 93.8%(30/32), 95.5%(42/44) and 91.9%(34/37), the difference had no statistical significance(P>0.05). No obvious adverse drug reactions occurred in all three groups. The medicine expenses of group A, group B and group C were respectively(904.75±342.33) yuan,(756.13±397.20) yuan and(669.06±147.31) yuan. Group C had the lowest cost-effectiveness ratio and the most advantage of pharmacoeconomics, the sensitivity analysis also confirm this result. CONCLUSIONS: The above three treatments have the same effect on mycoplasma pneumoniae pneumonia in children, of which amoxicillin-clavulanate potassium combined with azithromycin has the lowest cost, with the most advantage of pharmacoeconomics.

关 键 词：抗菌药物 支原体肺炎 成本-效果分析 

分 类 号：R956[医药卫生—药学]